| CFIm25 links alternative polyadenylation to glioblastoma tumour suppression CP Masamha, Z Xia, J Yang, TR Albrecht, M Li, AB Shyu, W Li, EJ Wagner Nature 510 (7505), 412-416, 2014 | 417 | 2014 |
| Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells CP Masamha, DM Benbrook Cancer research 69 (16), 6565-6572, 2009 | 239 | 2009 |
| 3′ UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk HJ Park, P Ji, S Kim, Z Xia, B Rodriguez, L Li, J Su, K Chen, CP Masamha, ... Nature genetics 50 (6), 783-789, 2018 | 153 | 2018 |
| The contribution of alternative polyadenylation to the cancer phenotype CP Masamha, EJ Wagner Carcinogenesis 39 (1), 2-10, 2018 | 70 | 2018 |
| Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy CP Masamha, P LaFontaine Journal of cellular biochemistry 119 (7), 6136-6145, 2018 | 62 | 2018 |
| The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis D M Benbrook, C P Masamha Current cancer drug targets 11 (5), 586-599, 2011 | 55 | 2011 |
| Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation T Weng, J Ko, CP Masamha, Z Xia, Y Xiang, N Chen, JG Molina, S Collum, ... The Journal of clinical investigation 129 (5), 1984-1999, 2019 | 53 | 2019 |
| Development of flexible-heteroarotinoids for kidney cancer T Liu, CP Masamha, S Chengedza, KD Berlin, S Lightfoot, F He, ... Molecular cancer therapeutics 8 (5), 1227-1238, 2009 | 46 | 2009 |
| CFIm25 regulates glutaminase alternative terminal exon definition to modulate miR-23 function CP Masamha, Z Xia, N Peart, S Collum, WEI Li, EJ Wagner, AB Shyu RNA 22 (6), 830-838, 2016 | 40 | 2016 |
| The emerging roles of CFIm25 (NUDT21/CPSF5) in human biology and disease CP Masamha Wiley Interdisciplinary Reviews: RNA 14 (3), e1757, 2023 | 17 | 2023 |
| Development of a dietary formulation of the SHetA2 chemoprevention drug for mice DM Benbrook, NB Janakiram, V Chandra, G Pathuri, V Madka, ... Investigational new drugs 36, 561-570, 2018 | 9 | 2018 |
| Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma CP Masamha, TR Albrecht, EJ Wagner Journal of Hematology & Oncology 9, 1-5, 2016 | 6 | 2016 |
| The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma CP Masamha Biomarker research 5, 1-4, 2017 | 4 | 2017 |
| The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian … A Marjamaa, B Gibbs, C Kotrba, CP Masamha Scientific Reports 13 (1), 17476, 2023 | 3 | 2023 |
| Regulation of apoptosis, cell cycle progression and differentiation by SHetA2 in renal cancer cells is associated with alterations in Bcl-2, Cyclin D1 and E-Cadherin proteins T Liu, C Masamha, S Chengedza, D Benbrook, S Lightfoot Molecular Cancer Therapeutics 6 (11_Supplement), A5-A5, 2007 | 3 | 2007 |
| Adapting 3'Rapid Amplification of CDNA Ends to Map Transcripts in Cancer CP Masamha, Z Todd Journal of Visualized Experiments: JoVE, 2018 | 2 | 2018 |
| SHetA2 targets cyclin D1 for proteasomal degradation through a GSK3β-independent mechanism leading to G1 cell cycle arrest. C Masamha, T Liu, D Benbrook Molecular Cancer Therapeutics 6 (11_Supplement), A116-A116, 2007 | 2 | 2007 |
| Author Correction: CFIm25 links alternative polyadenylation to glioblastoma tumour suppression CP Masamha, Z Xia, J Yang, TR Albrecht, M Li, AB Shyu, W Li, EJ Wagner Nature 612 (7940), E11-E11, 2022 | 1 | 2022 |
| Multiple Mechanisms Driving Alternative Polyadenylation of Cyclin D1 (CCND1) pre‐mRNA Processing CP Masamha, E Wagner The FASEB Journal 32, 650.12-650.12, 2018 | 1 | 2018 |
| Alternative 3′-RNA Processing in Cancer CP Masamha RNA-based Mechanisms in Cancer, 63-84, 2024 | | 2024 |
Eric J. WagnerProfessor, University of Rochester在 urmc.rochester.edu 的电子邮件经过验证
